Profile data is unavailable for this security.
About the company
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
- Revenue in USD (TTM)0.00
- Net income in USD-27.73m
- Incorporated2009
- Employees50.00
- LocationESSA Pharma Inc999 West Broadway, Suite 720VANCOUVER V5Z 1K5CanadaCAN
- Phone+1 (778) 331-0962
- Fax+1 (778) 331-0962
- Websitehttps://www.essapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cibus Inc | 2.32m | -285.67m | 224.91m | 183.00 | -- | 0.6881 | -- | 96.94 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
Chromadex Corp | 83.17m | -3.53m | 225.11m | 106.00 | -- | 7.74 | -- | 2.71 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Inhibrx Biosciences Inc | 1.78m | -271.16m | 227.27m | 166.00 | -- | 66.82 | -- | 127.47 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Fibrobiologics Inc | 0.00 | -22.53m | 232.63m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 232.91m | 49.00 | -- | 5.24 | -- | 2,875.39 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 233.01m | 133.00 | -- | 1.26 | -- | 219.00 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Ovid Therapeutics Inc | 473.53k | -50.68m | 233.41m | 40.00 | -- | 2.97 | -- | 492.91 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Omeros Corp | 0.00 | -179.09m | 235.25m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 235.53m | 122.00 | -- | 2.25 | -- | 328.46 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
ESSA Pharma Inc | 0.00 | -27.73m | 238.23m | 50.00 | -- | 1.78 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Zura Bio Ltd | 0.00 | -60.18m | 240.09m | 14.00 | -- | 2.69 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Renovaro Inc | 0.00 | -53.93m | 241.91m | 11.00 | -- | 1.43 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Aquestive Therapeutics Inc | 51.50m | -28.77m | 244.89m | 135.00 | -- | -- | -- | 4.76 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
Data as of Jun 14 2024. Currency figures normalised to ESSA Pharma Inc's reporting currency: US Dollar USD
76.70%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Mar 2024 | 8.75m | 19.72% |
Bellevue Asset Management AGas of 31 Mar 2024 | 7.89m | 17.78% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 4.18m | 9.42% |
Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 3.59m | 8.09% |
PFM Health Sciences LPas of 31 Mar 2024 | 2.98m | 6.72% |
RTW Investments LPas of 31 Mar 2024 | 2.30m | 5.18% |
Adage Capital Management LPas of 31 Mar 2024 | 1.58m | 3.56% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.18m | 2.65% |
Rhenman & Partners Asset Management ABas of 31 Mar 2024 | 911.82k | 2.06% |
Rock Springs Capital Management LPas of 31 Mar 2024 | 677.01k | 1.53% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.